Related Experiment Video
Updated: Jul 10, 2026
07:07
Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
Published on: May 2, 2017
Robust parameter estimation in a model for glucose kinetics in type 1 diabetes subjects
Cesar C Palerm1, María Rodríguez-Fernández, Wendy C Bevier
1Dept. of Chemical Engineering University of California Santa Barbara, CA 93106-5080, USA.
Summary
This study adapted a mathematical model for type 1 diabetes, improving glucose and insulin dynamics simulation. The validated model aids in developing artificial pancreas systems for better diabetes management.
Area of Science:
- Biomedical Engineering
- Endocrinology
- Computational Biology
Background:
- Developing closed-loop insulin delivery systems requires accurate mathematical models.
- Existing models were often based on non-diabetic subjects, limiting their applicability.
Purpose of the Study:
- To adapt and validate a physiological mathematical model for glucose and insulin dynamics in type 1 diabetes subjects.
- To assess the model's capability in simulating subject responses under specific experimental conditions.
Main Methods:
- Modified a published Hovorka et al. model by integrating the Wilinska et al. subcutaneous insulin infusion model.
- Utilized data from five type 1 diabetes subjects undergoing a hyperinsulinemic-euglycemic clamp with a meal challenge.
- Employed global optimization methods to fit model parameters to collected experimental data.
Main Results:
- The adapted model successfully described glucose and insulin dynamics in type 1 diabetes subjects during the clamp study.
- Parameter fitting using global optimization yielded a model capable of representing observed physiological responses.
Conclusions:
- The modified mathematical model is suitable for simulating type 1 diabetes subject behavior under experimental conditions.
- This validated model can be a valuable tool for testing and developing closed-loop control algorithms for artificial pancreas systems.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...